Search PubMed⌕ Search

Biomedical subjects

M F Attie

Publications and source records attributed to M F Attie.

27 records · Page 2Linked to original sources
PubMed1980

Characterization of the dopamine-responsive adenylate cyclase of bovine parathyroid cells and its relationship to parathyroid hormone secretion.

To investigate further the mechanism of dopamine (DA)-stimulated and parathyroid hormone (PTH) secretion, we have identified and studied DA-sensitive adenylate cyclase in a particulate preparation of osmotically lysed dispersed bovine parathyroid cells. Adenylate cyclase was responsive to DA at concentrations as low as 0.3 microM, and the maximal stimulation in the presence of GTP was 2- to 4-fold that of activity with GTP alone. (-)Propranolol (1 microM) abolished the stimulation by (-)isoproterenol but did not inhibit the DA-stimulated adenylate cyclase, whereas alpha-flupenthixol (1 microM) inhibited DA stimulation but not that of (-)isoproterenol. The dopaminergic agonists epinine and 6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene were nearly as effective as DA in stimulating the enzyme, while apomorphine displayed partial agonist activity. The dopaminergic antagonists chlorpromazine, fluphenazine, and haloperidol inhibited the DA-stimulated adenylate cyclase. There was a close correspondence between the Ka values for DA and the Ki values of the dopaminergic antagonists for particulate adenylate cyclase activity, cellular cAMP accumulation, and PTH release. These results indicate that DA-stimulated cAMP accumulation and PTH release are mediated through specific activation of a DA receptor linked to adenylate cyclase.

Adenylyl Cyclases↗
PubMed1980

Adenosine 3',5'-monophosphate response to parathyroid hormone: familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism.

We investigated cAMP metabolism during and after a 15-min infusion of parathyroid hormone (PTH) in 7 normals, 13 patients with typical primary hyperparathyroidism (1HPT), and 6 patients with familial hypocalciuric hypercalcemia (FHH). Nephrogenous urinary cAMP excretion rate reached a peak during the first or second 30 min urine collection interval after the start of the PTH infusion in all subjects. cAMP concentration in plasma reached a peak within 5--20 min of the start of the infusion and then decreased with an initial half-time of 15 min. The peak value of nephrogenous urinary cAMP excretion rate was lower in the group with 1HPT than in the group with FHH or in normals (119 vs, 275 vs. 204 nmol/100 ml glomerular filtrate; P less than 0.0 5 for both comparisons). Similarly, the peak value of plasma cAMP concentration was less in 1HPT subjects than in FHH patients or in normals (11.1 vs. 17.1 vs. 16.6 nmol/100 ml, respectively; P less than 0.05 for both comparisons). For purposes of diagnostic classification, the two hypercalcemia groups could be more completely separated by the values of either the renal calcium to creatinine clearance ratio or the plasma PTH concentration than by the values of inidices of cAMP response to PTH. The differences in cAMP response to PTH between FHH and 1HPT patients could be secondary to differences in circulating PTH concentrations (these are lower in subjects with FHH) or could reflect a renal lesion more closely related to the underlying etiology of FHH.

Cyclic AMP↗
PubMed1980

Prostaglandin-mediated stimulation of adenosine 3',5'-monophosphate accumulation and parathyroid hormone release in dispersed human parathyroid cells.

Freshly dispersed cells were employed to study the effects of various prostaglandins (PGs) on cAMP accumulation and parathyroid hormone release in abnormal human parathyroid tissue. PGE1 and PGE2 effected dramatic increases in intracellular cAMP accumulation over a concentration range of 10(-6)-10(-4) M; the relative effectiveness of these agents varied among different preparations. PGF2 alpha caused a smaller stimulation of cAMP accumulation, and PGF1 alpha was generally without effect. In contrast with the effect previously described in the bovine parathyroid cell system, PGF2 alpha did not suppress agonist-stimulated cAMP accumulation. Both PGE1 and PGE2 enhanced cellular release of parathyroid hormone, with dose-response characteristics similar to those seen with cAMP. In addition, both agents led to a significant stimulation of adenylate cyclase activity in a cellular homogenate preparation. Neither indomethacin (10(-5) M) nor naproxen (10(-4) M) altered the calcium suppressibility of the cells, suggesting that endogenous PG production does not play a major role in the calcium-mediated regulation of parathyroid hormone release.

Animals↗
PubMed1980

Familial hypocalciuric hypercalcemia: recognition among patients referred after unsuccessful parathyroid exploration.

Of 67 patients referred after unsuccessful surgery for presumed primary hyperparathyroidism, six were shown to be members of kindreds with familial hypocalciuric hypercalcemia. This diagnosis had not been recognized in any of the six previosuly. Most of the remaining 61 cases had proven or probable typical primary hyperparathyroidism, and a subgroup of four had hypercalcemia with suppression of the parathyroid glands. Urine calcium excretion expressed as the calcium:creatinine clearance ratio provided an easily measurable and effective index to separate the groups with familial hypocalciuric hypercalcemia, typical primary hyperparathyroidism, and suppressed parathyroids. Thus, at least 9% of patients referred after unsuccessful parathyroidectomy had familial hypocalciuric hypercalcemia. The assessment of urine calcium excretion by indices such as the calcium:creatinine clearance ratio should facilitate recognition of this condition, which responds poorly to standard subtotal parathyroidectomy.

Adult↗
PubMed1980

Urinary cyclic 3',5'-adenosine monophosphate (cAMP): an index of the action of parathyroid hormone on the kidney.

Quantitation of cAMP in plasma and urine allows derivation of indices or renal responsiveness to PTH, indices of steady-state circulating PTH bioactivity, and indices of rapid changes in circulating PTH bioactivity. For each of these three applications, we have cited examples, primarily from our clinical experience, of abnormally high and abnormally low values of the measured indices.

Calcium↗